Skip to main content
      Interesting look into autoantibody profile of rheumatic disease-ILD compared to IPF
      Identified 7 ab in RD-ILD, emphasizi

      Robert B Chao, MD

      1 year ago
      Interesting look into autoantibody profile of rheumatic disease-ILD compared to IPF Identified 7 ab in RD-ILD, emphasizing lack of autoimmunity in IPF Different mechanisms of damage and progression based on ab profile? @RheumNow #ACR23 Abs#2572 https://t.co/5rtXnOe9oJ
      #ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis

      -Anti-NT5c1A assoc with dysphagia
      -Anti-Ro52/TRIM21: fema

      Md Yuzaiful Md Yusof

      1 year ago
      #ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis -Anti-NT5c1A assoc with dysphagia -Anti-Ro52/TRIM21: female -Anti-VCP: male -Anti-NT5c1A + clinical markers: high accuracy in separating SIBM vs AIM Need longitudinal data for clusters to be meaningful @RheumNow https://t.co/fu0a074XAZ
      Beware of the « HOT stuff 🌶️ bias »

      In his very didactic catalogue of bias, Timothy McAlindon particularly wa

      Aurelie Najm

      1 year ago
      Beware of the « HOT stuff 🌶️ bias » In his very didactic catalogue of bias, Timothy McAlindon particularly warns us against the hot stuff, or the tendency to be less rigorous in the scientific approach when a topic is fashionable @RheumNow #ACR23 https://t.co/rS8lItDrGS
      #ACR23 Abstr#2580 Could high-intensity resistance training improve outcomes in myositis? RCT showed 16 wks of training w

      Md Yuzaiful Md Yusof

      1 year ago
      #ACR23 Abstr#2580 Could high-intensity resistance training improve outcomes in myositis? RCT showed 16 wks of training was tolerable, improved quality of life & functional capacity, without increasing disease activity/damage @RheumNow https://t.co/O1nP2x9C1L
      #ACR23 BEST Abstracts from San Diego – Day 1

      From hundreds of online presentations, the poster floor and the plenary

      Dr. John Cush RheumNow

      1 year ago
      #ACR23 BEST Abstracts from San Diego – Day 1 From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from 11/12/23. You can spot these on Twitter by looking for the (#ACRbest) hashtag. https://t.co/h4RvFy66z9 https://t.co/LEhAUaw6Cj
      Do Probiotics Improve PsA?
      Probiotics and gut microbiome is a hot topic in the research world and amongst patients. Oft

      Dr. John Cush RheumNow

      1 year ago
      Do Probiotics Improve PsA? Probiotics and gut microbiome is a hot topic in the research world and amongst patients. Often, one the questions I get after sharing the diagnosis of PsA is, “Is there anything I can eat/not eat to make this better?” #ACR23 https://t.co/aK56UXz3gs https://t.co/p2AuzcWyq9
      Who gives a ‘JAK’ why and how they work, as long as they do!

      Several abstracts have studied the mechanism of actio

      Dr. John Cush RheumNow

      1 year ago
      Who gives a ‘JAK’ why and how they work, as long as they do! Several abstracts have studied the mechanism of action of JAKi in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. #ACR23 https://t.co/xqQF8SULgp https://t.co/DZtEly8GEq
      RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? CLICK here to answer: htt

      Dr. John Cush RheumNow

      1 year ago
      RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? CLICK here to answer: https://t.co/afJmqzzPYi
      These year’s annual ACR Convergence has been a success with the return of an insanely active Poster Hall! F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be.
      #ACR23 Daily Recap Panel - Day 1

      Join our live stream panel discussion as we dive deep into the highlights and key tak

      Dr. John Cush RheumNow

      1 year ago
      #ACR23 Daily Recap Panel - Day 1 Join our live stream panel discussion as we dive deep into the highlights and key takeaways from day one of ACR 2023. https://t.co/hApuycYzD2 https://t.co/1CD3rLLV7D
      For as long as I can remember, methotrexate has been the anchor drug treatment of rheumatoid arthritis. We also know it has limited oral bioavailability at doses greater than 15mg. There are subcutaneous forms that offer better bioavailability, but its subcutaneous nature can sometimes sway patients away from trying it in addition to its higher cost. Split dosing of methotrexate can be a solution to attain higher bioavailability; however, its